The Board has considered and took on record the un-audited standalone financial results for the quarter ended December 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.0 pts less than Nifty Microcap 250 and 10.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Samrat Pharmachem reported weak Q3 FY26 results with revenue from operations of Rs 6,342.61 lakhs, down about 20% from Rs 7,887.03 lakhs in the previous quarter (Q2 FY26) and marginally lower than Rs 6,366.12 lakhs in Q3 FY25. For the 9-month period, revenue was Rs 21,794.80 lakhs versus Rs 21,465.74 lakhs last year, a marginal 1.5% rise, but total expenses grew faster to Rs 22,019.61 lakhs. The company slipped into a loss, posting a profit before tax of negative Rs 110.77 lakhs for 9M FY26 against a profit of Rs 1,024.96 lakhs in 9M FY25. Profit after tax for 9M FY26 was a loss of Rs 127.57 lakhs compared to a profit of Rs 751.14 lakhs last year, translating to a loss per share of Rs 4.13 versus earnings of Rs 24.31 earlier. The statutory auditor (Shah & Savla LLP) issued an unmodified limited review report with no qualifications.
Sharp swing from profit to loss and a sequential revenue drop of around 20% point to significant margin pressure and weak quarterly performance, which is likely negative for the stock and reflects poorly on near-term shareholder returns.